Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease

Chronic kidney disease (CKD) will progress to end stage without treatment, the decline off renal function may not linear. A sensitive marker such as soluble urokinase-type plasminogen activator receptors (suPARs) may allow potential intervention and treatment in earlier stages of CKD.Objectives:This study was designed to measure plasma (suPAR) in patients with CKD with different stages and to find its correlation with the disease severity.Methods:This study was conducted on 114 subjects, 84 were patients with different stages and different causes of CKD, and 30 healthy subjects as controls. Blood urea, serum creatinine, serum high-sensitive C-reactive protein, estimated glomerular filtration rate, and 24hours proteinuria were measured, renal biopsy was done for all patients, and plasma (suPAR) was measured using enzyme-linked immunosorbent assay.Results:suPAR plasma levels were significantly higher in patients with CKD (7.9±3.82ng/mL) than controls (1.76±0.77ng/mL, P<.001). suPAR correlated with the disease severity. In stage 1 to 2 group, it was 3.7±1.5ng/mL, in stage 3 to 4, it was 10.10±1.22ng/mL, and in stage 5 group, it was 12.34±0.88ng/mL; the difference between the 3 groups was highly significant (P<.001). A cutoff point 2.5ng/mL of suPAR was found between controls and stage 1 group. According to the cause of CKD, although patients with obstructive cause and those with focal glomerulosclerosis had the higher levels 9.11±3.32ng/mL and 8.73±3.19ng/mL, respectively, but there was no significant difference between patients with CKD according to the cause of the CKD.Conclusion:Plasma (suPAR) increased in patients with CKD and correlated with disease severity.